, 2007). Expansion of the limited thoracic volume, where extra-pulmonary restriction may be caused by competition between the lungs and heart for intrathoracic space, can lead to imbalance in the thoracoabdominal system. As the disease progresses and worsens, associated with cardiomegaly, minor effort leads to more frequent and severe dyspnea episodes and early muscle fatigue sets in (Ulrik

et al., 1999). Optoelectronic plethysmography (OEP) is used to elucidate the influence of cardiomegaly in regional distribution of ventilation TGF-beta inhibitor in the thoracoabdominal system of CHF patients (Aliverti and Pedotti, 2003). No studies were found in the literature using used the technique for this population. Therefore, the hypothesis for this study is that individuals with CHF and cardiomegaly associated with diaphragmatic

weakness exhibit volumetric differences in the thoracoabdominal system during the inspiratory loaded breathing (ILB) test when compared to healthy subjects. The present study aimed to investigate whether alterations in regional chest wall displacement, reflecting abnormalities in respiratory muscle action, are present in CHF patients with cardiomegaly, and if these alterations are related to other functional parameters, namely dyspnea. This was a cross-sectional cohort study in which a total of 31 individuals were evaluated and divided into two groups: CHF and control. In the CHF group, nineteen patients diagnosed with CHF were recruited from an outpatient clinic at a hospital cardiac center from May to December 2010, according to the following Buparlisib mouse inclusion criteria: sedentary adults aged between 21 and 65 years; Reverse transcriptase both

sexes; diagnosed with CHF associated with cardiomegaly; functional class II and III; hypertensive, ischemic, and Chagas disease etiology; left ventricular ejection fraction (EF) < 45%; inspiratory muscle weakness (predicted MIP < 70%) (Neder et al., 1999); clinical stability (>3 months); duration of symptoms > 1 year, body mass index (BMI) < 35 kg/m2 and non-smokers or former smokers with a smoking history <10 packs/year. Patients with the following characteristics were not considered: unstable angina; myocardial infarction or cardiac surgery in the three months prior to the start of the research; orthopedic diseases or respiratory comorbidities such as asthma and COPD. All patient medication was optimized for CHF throughout the study. The control group consisted of twelve volunteer participants with similar age, sex, and body mass index to the CHF group. Control participants displayed a left ventricular ejection fraction (EF) > 50% and had no cardiac chamber abnormalities, history of hypertension, lung disease, or cardiac ischemia; MIP 80% above (Neder et al., 1999) that predicted, in addition to being sedentary. All participants were instructed regarding the research and signed informed consent.